What is AlgiSys?
Founded in 2009 by Mr. LoPresti and Dr. Roe, AlgiSys operates at the intersection of advanced biotechnology and sustainable resource development. The company is primarily focused on the commercialization of over a decade of proprietary algae research. By leveraging specialized biological processes, AlgiSys aims to address critical gaps in the global supply chain for high-value nutritional and industrial compounds. Its position in the Cleveland biotech ecosystem allows it to tap into regional research talent while maintaining a global outlook on the scalability of its algae-derived products. The firm's operational model is built upon the premise that sustainable, algae-based solutions can provide a viable alternative to traditional, resource-intensive production methods.
How much funding has AlgiSys raised?
AlgiSys has raised a total of $51.4M across 3 funding rounds:
Angel/Seed
$200K
Series A
$6.2M
Series B
$45M
Angel/Seed (2011): $200K, investors not publicly disclosed
Series A (2013): $6.2M, investors not publicly disclosed
Series B (2021): $45M supported by Peakstone Securities
Key Investors in AlgiSys
Peakstone Securities
An investment banking firm providing strategic advisory and capital raising services to middle-market companies across various sectors.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for AlgiSys?
With the successful closure of its latest financing round, AlgiSys is positioned to accelerate its commercialization roadmap. The strategic deployment of these funds will likely focus on scaling production infrastructure and expanding the firm's market reach for its core algae-based offerings. As the company moves deeper into the post-Series B phase, the focus will shift toward optimizing supply chain efficiencies and securing long-term partnerships with industrial stakeholders. The management team is expected to prioritize the transition from research-heavy development to high-volume manufacturing, ensuring that the firm's intellectual property is effectively translated into tangible market value. Continued monitoring of the firm's operational milestones will be essential as it seeks to solidify its standing as a leader in the sustainable biotechnology space.
See full AlgiSys company page
